GLP-1 frequently asked questions

Wegovy's list price is about $1,349/month without insurance. Novo Nordisk's direct cash-pay program (NovoCare) has offered the pen for around $349/month for maintenance doses ($199/month introductory) to people paying out of pocket, and commercially insured patients may pay $0-225/month with the savings card (as of 2026 — confirm current program terms).

It varies widely. Wegovy is FDA-approved for chronic weight management, but many commercial plans explicitly exclude weight-loss drugs, and historically Medicare did not cover medications for obesity alone (this is shifting now that Wegovy carries an added cardiovascular indication). Coverage often hinges on your specific plan's formulary and documented medical need.

Compounded semaglutide via telehealth ($150-300/month) is the lowest-cost route but is not FDA-approved as a finished product. Zepbound (tirzepatide) is the other leading on-label weight-loss drug and sometimes has a lower net cost via the manufacturer's self-pay vials. Saxenda is an older, daily option. We compare these and redirect to licensed providers — we sell nothing ourselves.

Their list prices are similar (~$1,300 vs ~$1,000/month), but the real out-of-pocket cost depends on coverage and programs. Because Wegovy is approved for weight management, some weight-focused patients get better coverage or access to its NovoCare cash program (from ~$199/mo introductory, ~$349 maintenance); Ozempic's savings card requires a diabetes diagnosis. Compare both against your own plan.

Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist. It slows gastric emptying so you feel full longer, reduces appetite and food cravings by acting on brain appetite centers, and improves glucose-dependent insulin release. In the STEP trials this drove a mean ~15% body-weight reduction over 68 weeks alongside diet and activity. Educational overview, not medical advice.

Appetite changes are often noticeable within the first weeks, but Wegovy is titrated over about 16-20 weeks to the 2.4 mg maintenance dose, and weight loss continues over roughly a year in the trials. A prescriber decides the titration — this is not a self-dosing plan.

Wegovy is a once-weekly subcutaneous injection given in the abdomen, thigh, or upper arm, rotating sites. The single-use autoinjector delivers a fixed dose when held against the skin; follow the Instructions for Use and your prescriber's guidance.

There is no mandatory Wegovy diet, but adequate protein, smaller portions (appetite is reduced), and easing off greasy or very sweet foods help many people tolerate it and preserve muscle during weight loss. Our GLP-1 diet guide covers this in depth. General information, not medical advice.

Zepbound's list price is about $1,086/month for autoinjector pens. Eli Lilly's direct self-pay program (LillyDirect) offers single-dose vials at roughly $299–$699/month depending on strength, which is the cheapest brand route for cash-pay patients. Savings cards can lower the cost further for those with commercial insurance (as of 2026).

Coverage is inconsistent. Zepbound is FDA-approved for weight management (and now obstructive sleep apnea), but many plans exclude weight-loss drugs and Medicare coverage for obesity alone has been limited. The added sleep-apnea indication is expanding some coverage. Check your plan's formulary and consider Lilly's self-pay vials if you are uninsured.

On price they are now comparable: Lilly's self-pay vials run ~$299–$699/month and Wegovy's NovoCare cash program is ~$349/month maintenance ($199 introductory). Zepbound (tirzepatide) produced greater average weight loss in trials (~22% vs ~15%). The right choice still depends on your coverage, tolerance, and prescriber's judgment — compare both before deciding.

No. They are different drugs. Zepbound is tirzepatide (a dual GLP-1/GIP agonist) made by Eli Lilly and FDA-approved for weight management and obstructive sleep apnea. Ozempic is semaglutide (a GLP-1 agonist) made by Novo Nordisk and FDA-approved for type 2 diabetes. Different molecules, makers, and approved uses — Zepbound also produced more average weight loss in trials (~22% vs Ozempic-dose semaglutide).

Zepbound (tirzepatide) is FDA-approved for two things: chronic weight management in adults with obesity (or overweight plus a weight-related condition), and — since December 2024 — moderate-to-severe obstructive sleep apnea in adults with obesity. It is not approved for type 2 diabetes; that is its sister brand, Mounjaro (same molecule).

LillyDirect is Eli Lilly's direct self-pay channel that ships Zepbound single-dose vials (roughly $299–$699/month depending on strength) — usually the cheapest brand route for cash-pay patients. You still need a valid prescription from a licensed clinician (your own provider or a telehealth provider); you then order through LillyDirect for home delivery. It is self-pay, so insurance is not billed. Confirm current vial pricing and availability before ordering.

In trials, the highest maintenance doses (10 mg and 15 mg) produced the greatest average weight loss, but Zepbound is started low (2.5 mg) and increased gradually to limit nausea — the "best" dose is the highest one you tolerate that your prescriber sets, not necessarily the maximum. Never adjust your own dose; titration and the target dose are decided with your clinician.

Ozempic's list price is about $969-998/month for the cash-pay pen without insurance or coupons (as of 2026). Commercially insured patients may pay as little as $25/month with the Novo Nordisk savings card; Medicare and Medicaid pricing differ. Because Ozempic is FDA-approved for type 2 diabetes (not weight loss), plans frequently deny coverage when it is prescribed off-label for weight, leaving patients facing the full list price.

There is no generic version — semaglutide is patent-protected in the U.S. into the early 2030s, so a single manufacturer (Novo Nordisk) sets the price. It is also a biologic peptide that is complex to make, demand far outstrips supply, and U.S. list prices are not negotiated the way they are in most other countries. These factors keep the cash price near $1,000/month.

Yes. Compounded semaglutide via telehealth runs roughly $150-300/month (same active ingredient, but not FDA-approved as a finished product). Rybelsus is an oral semaglutide from the same maker. For weight loss specifically, Wegovy and Zepbound are the on-label options. We do not sell any of these — compare the trade-offs and pricing on our drug pages, then we redirect you to a licensed provider.

Options include: the manufacturer savings card if you have commercial insurance, the NovoCare patient-assistance program if you are low-income and uninsured, cash-pay telehealth programs, asking your prescriber to submit a prior-authorization appeal, or considering lower-cost compounded semaglutide (with the regulatory caveats). Pharmacy price varies, so it is worth comparing.

Ozempic (semaglutide) is a GLP-1 receptor agonist. It mimics a natural gut hormone: it slows how fast the stomach empties so meals feel filling for longer, prompts the pancreas to release insulin only when blood sugar is high (a glucose-dependent effect that keeps hypoglycemia risk low on its own), lowers the glucagon that raises blood sugar, and acts on appetite centers in the brain. Together those effects lower A1c and reduce appetite. This is general education, not medical advice.

Blood-sugar effects begin within the first week, but the dose is titrated slowly over 8+ weeks and the full A1c and appetite effect builds over about 2-3 months. Weight change, where it happens, is gradual over months. A prescriber sets and adjusts the dose — this is not a self-titration schedule.

The FDA label lists three subcutaneous sites — the abdomen, front of the thigh, and back of the upper arm — rotated between doses. The pen is used once weekly on the same day. Follow the Instructions for Use that come with the pen and your prescriber's guidance for technique.

No food is strictly off-limits, but because Ozempic slows gastric emptying, greasy, fried, very sweet, or large meals commonly worsen nausea while the body adjusts; smaller, lower-fat, protein-forward meals tend to be better tolerated. See our GLP-1 foods-to-avoid and diet guides for detail. General comfort information, not medical advice.

Mounjaro's list price is about $1,069/month without insurance. Commercially insured patients with type 2 diabetes may pay as little as $25/month with the Eli Lilly savings card. Mounjaro is approved for diabetes, not weight loss — when prescribed off-label for weight, coverage is often denied, exposing the full price.

Like Ozempic, tirzepatide has no generic and a single manufacturer (Eli Lilly) holding patents into the 2030s. It is a dual GLP-1/GIP biologic that is costly to produce, demand is high, and U.S. list prices are unregulated. The result is a cash price above $1,000/month.

Compounded tirzepatide via telehealth ($200-450/month) is the cheapest option but is not FDA-approved as a finished product. Zepbound is the same molecule approved for weight loss and has lower-cost self-pay vials. Ozempic/Wegovy (semaglutide) are alternative-class choices. We list pricing and redirect to licensed providers rather than selling anything.

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist — it activates two gut-hormone receptors at once. Like a GLP-1 drug it slows gastric emptying, boosts glucose-dependent insulin, and reduces appetite; the added GIP activity is thought to further improve how the body handles fat and sugar, which is linked to the larger average weight loss seen versus GLP-1-only drugs. Educational, not medical advice.

Blood-sugar effects start within the first week; the dose is titrated in 2.5 mg steps no sooner than every 4 weeks, and the full A1c and weight effect builds over a few months. A prescriber sets the schedule — do not self-titrate.

Mounjaro is injected under the skin once weekly in the abdomen, thigh, or upper arm, rotating sites. Follow the Instructions for Use and your prescriber's guidance for the pen and technique.

Rybelsus has a list price of approximately $998/month for 30 tablets, comparable to Ozempic. Manufacturer NovoCare savings cards can reduce commercially-insured copays significantly. Cash-pay prices vary by pharmacy. Rybelsus is FDA-approved only for type 2 diabetes; insurance coverage is generally consistent for that indication.

Rybelsus is not FDA-approved for weight loss. Average weight loss in PIONEER trials was 2.3-4.4 kg over 26 weeks — substantially less than injectable semaglutide (Wegovy averaged 14.9% in STEP-1). Off-label use exists, but for weight management specifically, Wegovy or Zepbound are the on-label FDA-approved choices.

Take Rybelsus on an empty stomach in the morning with no more than 4 ounces of plain water. Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Bioavailability is only 0.4-1% — strict timing is required for the absorption enhancer (SNAC) to work. Skipping the 30-minute rule can substantially reduce drug effect.

Both contain semaglutide. Rybelsus is the oral tablet form (3-14mg daily); Ozempic is the weekly subcutaneous injection (0.25-2mg). Same molecule, very different formulations and bioavailability profiles. Ozempic achieves higher systemic exposure and stronger A1C/weight effects; Rybelsus is needle-free but requires strict empty-stomach dosing daily.

Saxenda's list price is approximately $1,349/month — the same tier as Wegovy — and there is no savings card to bring it down: Novo Nordisk closed the Saxenda Savings Offer to new enrollees on June 30, 2023 and existing cards stopped working after that December. Generic liraglutide at roughly $469/month cash is the cheaper way to the same molecule, though ${LIRAGLUTIDE_SUPPLY_SHORT}. Brand cash-pay Saxenda is rarely a value choice in 2026 because Wegovy and Zepbound offer weekly dosing at comparable or lower cost. The exception: pediatric patients (Saxenda and Wegovy are the two GLP-1s approved for ages 12+).

No. Saxenda contains liraglutide (daily injection, 3mg); Wegovy contains semaglutide (weekly, 2.4mg). Both are FDA-approved for chronic weight management but use different active ingredients. Wegovy produced higher average weight loss in trials (14.9% in STEP-1 vs 7.4% in SCALE-Obesity for Saxenda). Saxenda predates Wegovy by 7 years and has largely been superseded for new patients.

Yes, Saxenda remains commercially available. The FDA resolved the Saxenda shortage in May 2024. Usage has declined sharply with the launches of Wegovy (2021) and Zepbound (2023). Saxenda remains relevant primarily for adolescents (ages 12+ approval) and patients who tolerate liraglutide better than semaglutide individually.

Yes, switching is straightforward. Saxenda (liraglutide) and Wegovy (semaglutide) are different molecules in the same drug class. Your prescriber typically discontinues Saxenda then initiates Wegovy at the standard 0.25mg starter dose, regardless of your Saxenda dose. Some patients tolerate the switch better with a 1-2 week washout; others transition immediately. Discuss with your prescriber.

No. Trulicity (dulaglutide) is FDA-approved only for type 2 diabetes (glycemic control, plus cardiovascular risk reduction in adults with T2D and established cardiovascular disease). It is not approved for type 1 diabetes and is not a substitute for insulin — people with T1D require insulin therapy.

Trulicity's list price is approximately $987/month. Eli Lilly's manufacturer savings card can reduce commercial-insurance copays. Trulicity is FDA-approved for type 2 diabetes only — insurance coverage is generally consistent for that indication. It is not FDA-approved for weight loss, though it produces ~3% average weight reduction at the 1.5mg dose in trials.

Head-to-head trials (SURPASS-2 + related) showed Mounjaro (tirzepatide) achieved greater A1C reduction and weight loss vs Trulicity (dulaglutide). Mounjaro is the dual GIP/GLP-1 agonist with higher potency. Trulicity is older but valued for its very simple auto-injector device and 12% cardiovascular event reduction shown in REWIND. Choice depends on your priorities: maximum potency (Mounjaro) vs simplicity + CV data (Trulicity).

Trulicity produces modest weight loss — average 3% body weight at the 1.5mg dose over 52 weeks in REWIND. This is lower than semaglutide-based or tirzepatide-based GLP-1s. Trulicity is FDA-approved for type 2 diabetes and cardiovascular event reduction in adults with T2D plus established CVD, not for weight loss specifically.

No — Novo Nordisk discontinued Victoza (liraglutide 1.2/1.8 mg for diabetes) in April 2024. Existing prescriptions may still be filled while pharmacy supply lasts, but no new manufacturing is occurring. Patients should discuss alternatives with their prescriber. Saxenda (liraglutide 3.0 mg, for weight management) remains available and uses the same active ingredient at a higher dose.

There is no direct generic-style replacement for Victoza. Novo Nordisk continues Saxenda (the higher-dose liraglutide for weight). For diabetes patients on Victoza, prescribers typically transition to Ozempic (weekly semaglutide), Trulicity (weekly dulaglutide), Mounjaro (weekly tirzepatide), or Rybelsus (oral semaglutide), based on clinical factors and insurance coverage.

Novo Nordisk did not publicly cite a specific reason for the April 2024 Victoza discontinuation. Industry observers note Victoza's 2010 approval put it among the older GLP-1s, with newer weekly options (Ozempic, Trulicity) capturing market share due to better adherence. Manufacturing capacity for liraglutide was likely reallocated to Saxenda and other priority products.

Compounded semaglutide uses the same active ingredient (semaglutide) as Ozempic, so the pharmacological effect is expected to be similar. The difference is regulatory: Ozempic is FDA-approved as a finished product with full manufacturing oversight, while compounded versions are NOT FDA-reviewed for safety, potency, or quality. Efficacy can vary by compounding pharmacy.

Compounded semaglutide from a state-licensed 503A pharmacy or 503B outsourcing facility, prescribed by a licensed clinician, is legal. However, the FDA has warned about fraudulent online sellers, mislabeled products, and unapproved "salt" forms (semaglutide sodium). Legitimacy depends on the specific pharmacy — verify accreditation and require a real prescription.

Availability is shrinking. After the FDA declared the semaglutide shortage resolved, the legal basis for mass-compounding narrowed, and the FDA has moved to permanently restrict compounded GLP-1s. Some 503A pharmacies still produce personalized formulations (e.g. with B12), but broad availability is being phased out as commercial supply stabilizes. Check current status with your provider.

Tirzepatide (the molecule in Mounjaro/Zepbound) produced greater average weight loss than semaglutide in head-to-head trials (~22% vs ~15%). Compounded tirzepatide therefore tends to deliver stronger results, but may cause more GI side effects and faces the same regulatory phase-out as compounded semaglutide.

Most patients lose roughly 1-2 pounds per week on semaglutide once titrated to an effective dose, so a 20-pound loss is typically achievable in about 10-16 weeks when paired with diet and activity. Higher starting weights often see faster early loss. Individual results vary widely.

Compounded semaglutide via telehealth typically runs $150-300/month cash-pay (some as low as ~$70-129 on intro pricing), versus $1,000-1,865/month list for FDA-approved Ozempic or Wegovy without insurance. The lower cost is the main reason patients choose compounded — weighed against reduced regulatory oversight.

Not banned outright as of 2026, but access is closing. After the FDA declared the semaglutide shortage resolved (February 2025), the shortage-based legal basis for mass-compounding ended, and the FDA has proposed permanently excluding semaglutide from the 503B outsourcing bulks list (public-comment period closed June 29, 2026; final rule pending). State-licensed 503A pharmacies may still compound personalized formulations with a valid prescription. Confirm current status with your provider.

Compounded semaglutide from a state-licensed 503A or 503B pharmacy with a valid prescription uses the same active ingredient as Ozempic and Wegovy, but compounded drugs are NOT FDA-reviewed for safety, potency, or quality, and the FDA has warned about fraudulent sellers and unapproved "salt" forms (semaglutide sodium/acetate). Safety depends on the specific pharmacy — verify accreditation, insist on a real prescription, and discuss the risks with your prescriber.

Cash-pay telehealth compounded semaglutide typically runs $150-300/month (some intro pricing ~$70-129) — compare the ranked provider prices on this page. Cheapest is not always best: weigh pharmacy accreditation and the not-FDA-approved trade-off, not price alone. GLP1Zoom compares licensed telehealth providers and redirects to them; we sell nothing ourselves.

Compounded tirzepatide uses the same active ingredient as Mounjaro and Zepbound, so the expected effect is similar. The distinction is regulatory: brand tirzepatide is FDA-approved with full oversight; compounded versions are not FDA-reviewed for safety, potency, or quality. Results can vary by compounding pharmacy.

Compounded tirzepatide from a licensed 503A/503B pharmacy with a valid prescription is legal, but the FDA has flagged fraudulent sellers and mislabeled products. Legitimacy depends on the specific pharmacy — verify accreditation and insist on a clinician prescription.

Like compounded semaglutide, availability is tightening. As tirzepatide comes off the FDA shortage list, the legal basis for compounding narrows and the FDA is restricting compounded GLP-1s. Some personalized formulations remain; broad availability is being phased out. Confirm current status with your provider.

Compounded tirzepatide via telehealth typically runs $200-450/month cash-pay, versus ~$1,000+/month list for brand Mounjaro or Zepbound without insurance. The cost savings drive demand, balanced against the regulatory trade-off.

Not banned outright as of 2026, but the legal basis has narrowed sharply. After the FDA declared the tirzepatide shortage resolved (December 2024), mass-compounding under the shortage exception ended, and the FDA has proposed permanently excluding tirzepatide from the 503B outsourcing bulks list (public-comment period closed June 29, 2026; final rule pending). State-licensed 503A pharmacies may still compound personalized formulations with a valid prescription. Confirm current status with your provider.

Compounded tirzepatide from a state-licensed 503A or 503B pharmacy with a valid prescription uses the same active ingredient as Mounjaro and Zepbound, but compounded drugs are NOT FDA-reviewed for safety, potency, or quality, and the FDA has warned about fraudulent online sellers and mislabeled "salt" forms (e.g. tirzepatide sodium). Safety depends on the specific pharmacy — verify accreditation, require a real clinician prescription, and discuss the trade-offs with your prescriber.

Cash-pay telehealth compounded tirzepatide typically runs $200-450/month — compare the ranked provider prices on this page. Cheapest is not always best: weigh pharmacy accreditation, the not-FDA-approved trade-off, and sterility/refund policies, not price alone. GLP1Zoom compares licensed telehealth providers and redirects you to them; we sell nothing ourselves.